Peregrine Pharmaceuticals Inc (PPHM) 1.80 $PPHM
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:24PM CDT
Medivation, Inc. (MDVN) entered into a research and license agreement with OncoFusion Therapeutics, Inc
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Marketwire - Wed Apr 23, 6:30AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy(R)), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of the SUNRISE pivotal Phase III clinical trial.
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer
Marketwire - Wed Apr 09, 10:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and demonstrating that the combination of a preclinical phosphatidylserine (PS)-targeting antibody with the immune checkpoint inhibitors anti-CTLA-4 or anti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma and colon cancer compared to anti-CTLA-4 and PD-1 antibodies alone. These data were presented yesterday and today as a late-breaking poster presentation and a poster presentation, respectively at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in second-line, non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Marketwire - Mon Apr 07, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy (SBRT) showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer (NSCLC) compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Investors look to Lighten Up on Shares of Peregrine Pharmaceuticals, Shares Down 9.8% (PPHM)
Comtex SmarTrend(R) - Mon Mar 24, 11:43AM CDT
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's worst performing low-priced stocks, down 9.8% to $2.02 on 1.0x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 5.3 million shares, vs. average volume of 5.3 million shares per day. The stock has underperformed the Dow (-9.8% to the Dow's -0.5%) and underperformed the S&P 500 (-9.8% to the S&P's -0.8%) during today's trading.
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:39AM CDT
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue?
Galena Biopharma vs. Peregrine Pharmaceuticals: Which is the Better Buy?
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 11:05AM CDT
For more than a year now you'd have difficulty finding a sector that has performed better on the market than health care. From Big Pharma down to medical device makers and small biotechs, health care has absolutely been on a tear. As such, it's been...
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Marketwire - Fri Mar 14, 7:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar(R)) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer. The oral presentation was given at the 67th Society of Surgical Oncology (SSO) Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Marketwire - Thu Mar 13, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Tue Mar 11, 3:11PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals (PPHM) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 10, 8:45AM CDT
Trade-Ideas LLC identified Peregrine Pharmaceuticals (PPHM) as a "dead cat bounce" (down big yesterday but up big today) candidate
Skullcandy and Foot Locker are big market movers
AP - Fri Mar 07, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:24PM CDT
Medivation, Inc. (MDVN) entered into a research and license agreement with OncoFusion Therapeutics, Inc
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Marketwire - Wed Apr 23, 6:30AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy(R)), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of the SUNRISE pivotal Phase III clinical trial.
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer
Marketwire - Wed Apr 09, 10:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and demonstrating that the combination of a preclinical phosphatidylserine (PS)-targeting antibody with the immune checkpoint inhibitors anti-CTLA-4 or anti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma and colon cancer compared to anti-CTLA-4 and PD-1 antibodies alone. These data were presented yesterday and today as a late-breaking poster presentation and a poster presentation, respectively at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in second-line, non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Marketwire - Mon Apr 07, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy (SBRT) showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer (NSCLC) compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Investors look to Lighten Up on Shares of Peregrine Pharmaceuticals, Shares Down 9.8% (PPHM)
Comtex SmarTrend(R) - Mon Mar 24, 11:43AM CDT
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's worst performing low-priced stocks, down 9.8% to $2.02 on 1.0x average daily volume. Thus far today, Peregrine Pharmaceuticals has traded 5.3 million shares, vs. average volume of 5.3 million shares per day. The stock has underperformed the Dow (-9.8% to the Dow's -0.5%) and underperformed the S&P 500 (-9.8% to the S&P's -0.8%) during today's trading. Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:39AM CDT
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue?
Galena Biopharma vs. Peregrine Pharmaceuticals: Which is the Better Buy?
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 11:05AM CDT
For more than a year now you'd have difficulty finding a sector that has performed better on the market than health care. From Big Pharma down to medical device makers and small biotechs, health care has absolutely been on a tear. As such, it's been...
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Marketwire - Fri Mar 14, 7:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar(R)) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer. The oral presentation was given at the 67th Society of Surgical Oncology (SSO) Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Marketwire - Thu Mar 13, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Tue Mar 11, 3:11PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
. Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals (PPHM) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 10, 8:45AM CDT
Trade-Ideas LLC identified Peregrine Pharmaceuticals (PPHM) as a "dead cat bounce" (down big yesterday but up big today) candidate
Skullcandy and Foot Locker are big market movers
AP - Fri Mar 07, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
